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Abstract
CD40-activated CD40L reverse signaling is a major physiological regulator of axon and dendrite growth from developing 
hippocampal pyramidal neurons. Here we have studied how CD40L-mediated reverse signaling promotes the growth of 
these processes. Cultures of hippocampal pyramidal neurons were established from Cd40−/− mouse embryos to eliminate 
endogenous CD40/CD40L signaling, and CD40L reverse signaling was stimulated by a CD40-Fc chimera. CD40L reverse 
signaling increased phosphorylation and hence activation of proteins in the PKC, ERK, and JNK signaling pathways. Phar-
macological activators and inhibitors of these pathways revealed that whereas activation of JNK inhibited growth, activation 
of PKC and ERK1/ERK2 enhanced growth. Experiments using combinations of pharmacological reagents revealed that these 
signaling pathways regulate growth by functioning as an interconnected and interdependent network rather than acting in 
a simple linear sequence. Immunoprecipitation studies suggested that stimulation of CD40L reverse signaling generated a 
receptor complex comprising CD40L, PKCβ, and the Syk tyrosine kinase. Our studies have begun to elucidate the molecular 
network and interactions that promote axon and dendrite growth from developing hippocampal neurons following activation 
of CD40L reverse signaling.
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Introduction
The growth and elaboration of neural processes during 
development and maturity have a major bearing on the 
establishment and modification of the functional properties 
of neural circuits. In addition to intrinsic developmental pro-
grams in neurons and the pattern of electrical activity, a wide 
variety of extrinsic signals orchestrate the growth, elabora-
tion and remodeling of axons and dendrites, including delta-
notch, Eph-Ephrins, cell adhesion molecules, neurotrophins, 
semaphorins, and slits [1, 2]. One of the latest groups of pro-
teins recognized to influence the growth of neural processes 
during development is the tumor necrosis factor superfamily 
(TNFSF). The 19 members of this superfamily bind to one or 
more members of the TNF receptor superfamily (TNFRSF) 
and are active as membrane-integrated ligands and as solu-
ble ligands following cleavage from the cell membrane 
[3]. In addition, several TNFRSF members can also act as 
ligands for the membrane-integrated TNFSF to which they 
bind, functioning as reverse signaling receptors [4]. While 
the TNF and TNFR superfamilies are best understood for 
their many roles in the immune system [5], several members 
of these superfamilies act on different kinds of neurons dur-
ing circumscribed phases of development, either enhanc-
ing or inhibiting the growth and elaboration of axons and/or 
dendrites by either forward or reverse signaling mechanisms 
[6–20].
Bidirectional signaling between membrane-integrated 
CD40 ligand (CD40L, TNFSR5) and CD40 (TNFRSF5) 
is a particularly important physiological regulator of axon 
and dendrite growth in many populations of neurons in the 
developing nervous system. In vivo analysis of wild type and 
Cd40−/− mice together with a variety of in vitro experiments 
have demonstrated that CD40L-activated CD40-mediated 
forward signaling promotes early sensory axon growth [20], 
whereas CD40-activated CD40L-mediated reverse signaling 
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promotes axon growth from subsets of sympathetic neurons 
[15], promotes dendrite and axon growth from hippocampal 
pyramidal neurons [18] and inhibits dendrite growth from 
striatal medium spiny neurons [18].
Given the extensive involvement of CD40-activated 
CD40L-mediated reverse signaling in regulating axon and 
dendritic growth in the developing peripheral and central 
nervous systems, the objective of the present study was to 
elucidate the key signaling networks downstream of CD40L 
that mediate this response in the well-characterized hip-
pocampal pyramidal neuron model. We focused on three 
signaling pathways that have been shown to play important 
roles in regulating the growth of neural processes from a 
variety of neurons, namely those utilizing protein kinase 
C (PKC), extracellular regulated kinases 1 and 2 (ERK1/
ERK2) and c-Jun N-terminal kinase (JNK). PKC is particu-
larly relevant because activation of PKC has been impli-
cated in mediating the effects of CD40L reverse signaling on 
dendrite growth from hippocampal pyramidal neurons and 
striatal medium spiny neurons [18]. PKC activation has also 
been implicated in the facilitation of axon growth by TNF 
reverse signaling [12, 16]. ERK1/ERK2 activation is neces-
sary for enhanced sympathetic axon growth in response to 
TNF reverse signaling [12] and for enhanced sensory axon 
growth in response to CD40 forward signaling [20]. ERK1/
ERK2 activation has also been implicated in enhanced neu-
rite growth to various factors [9, 21–23] and suppression 
of ERK1/ERK2 activation contributes to the suppression 
of axon growth by TWE-PRIL reverse signaling [19]. The 
JNK family has numerous functions in the nervous system 
including regulating dendrite growth and architecture [24].
Here we studied the effects of specific pharmacological 
inhibitors and activators of PKC, ERK1/ERK2, and JNK 
signaling on axon and dendrite growth from cultured hip-
pocampal pyramidal neurons. Our results have revealed that 
an interdependent network of signaling pathways mediate 
and regulate the actions of CD40L reverse signaling on the 
growth of axons and dendrites from hippocampal pyrami-
dal neurons. We have also begun to identify the molecular 
components of the CD40L receptor complex initiated by 
activation of reverse signaling.
Material and methods
Mice
Mice were housed in a 12 h light–dark cycle with access 
to food and water ad libitum. Breeding was approved by 
the Cardiff University Ethical Review Board and was per-
formed within the guidelines of the Home Office Animals 
(Scientific Procedures) Act, 1986. Cd40 null mutant mice in 
a C57BL6/J background were purchased from The Jackson 
Laboratory (Maine, USA). These mice were backcrossed 
into a CD1 background. Cd40+/− mice were crossed to gen-
erate Cd40−/− mice from which cultures were established.
Neuron culture
Primary hippocampal neuron cultures were prepared as 
described previously [25] with modifications. Briefly, hip-
pocampi were dissected from embryonic day 18 (E18) 
mouse embryos and were triturated to produce a single cell 
suspension following trypsin digestion (Worthington, Lake-
wood, USA) and DNase I treatment (Roche Applied Sci-
ence, East Sussex, UK). The neurons were plated in plastic 
dishes coated with poly-L -lysine (Sigma-Aldrich, Dorset, 
UK) at a density of 15,000 cells/cm2 for morphological 
analysis and of 21,000 cells/cm2 for western blot experi-
ments. The neurons were cultured in complete medium that 
contains Neurobasal A medium (Invitrogen, Paisley, UK) 
supplemented with 2% NeuroCult SM1 (StemCell, Cam-
bridge, UK), 0.5 mM GlutaMAX I (Invitrogen, Paisley, UK), 
100 units/ml penicillin, and 100 μg/ml streptomycin (Gibco 
BRL, Crewe, UK). The cultures were incubated at 37 °C in 
a humidified atmosphere containing 5% CO2. The culture 
medium was partially replaced with fresh complete medium 
every 4–5 days.
The cultures were treated as indicated in the text with 
the following reagents: Fc protein (1 μg/ml [18.87 nM], 
ALX-203–004-C050), CD40-Fc (1  μg/ml [18.52  nM], 
ALX-522–016-C050), U0126 (1 μM, BML-EI282-0001), 
and SP600125 (1 μM, BML-EI305-0010) from Enzo Life 
Sciences; Go6983 (500 nM, cat. no. 2285), Fisetin (1 μM, 
cat. no. 5016), U0124 (1 μM, cat. no. 1868) and Anisomycin 
(50 nM, cat. no. 1290) from Tocris Biosciences; phorbol-
12-myristate-13-acetate (PMA) (500 nM, MERCK, cat. 
no. 524400). Except for Fc protein and CD40-Fc that were 
reconstituted with sterile H2O, the rest was reconstituted 
in DMSO and subsequently diluted in culture medium to 
the concentrations indicated. No differences were observed 
between control cultures that received equivalent level of 
DMSO, untreated cultures, and cultures treated with Fc.
Analysis of dendrite and axon morphology
The neurite arbors of a subset of the neurons were visu-
alized by transfecting the neurons with a GFP expression 
plasmid after 7  days in vitro using lipofectamine 2000 
(Invitrogen, Paisley, UK) according to the manufacturer’s 
instructions with modifications. Briefly, the cultures were 
treated for 3 h with a mixture of the expression vector and 
lipofectamine, after which they were cultured for a further 
48 h. The neurons were then fixed for 30 min with 4% para-
formaldehyde. Fluorescent neurons were visualized using a 
Zeiss LSM710 confocal microscope. Dendrites and axons 
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were clearly distinguishable by their morphology, which 
permitted their lengths to be separately quantified [13, 25, 
26]. Total dendrite length and axon length were assessed 
using Fiji (ImageJ) software with the semiautomated plugin 
Simple Neurite Tracer [27]. The mean and standard errors 
of the measurements from multiple neurons in at least three 
independent experiments were plotted.
Prediction of protein–protein interactions 
with STRING
An in silico approach was used to determine possible pro-
tein–protein interactions (PPI) between CD40L and PKCβ 
using the STRING database (Search Tool for the Retrieval 
of Interacting Genes/Proteins, https://string-db.org/). Mouse 
CD40L and PKCβ were analyzed for all possible interactions 
including textmining, experiments, databases, co-expres-
sion, neighborhood, gene fusion, and co-occurrence with 
reliability scores more than 0.4 (where 0.4 corresponds to 
medium confidence). Supplemental Table 1 shows all pos-
sible PPI above at this confidence level for CD40L, PKCβ, 
and all that they share in common.
Downregulation of PKCβ
The level of PKCβ protein was specifically reduced using 
siRNA, as previously reported [18]. Briefly, neurons were 
transfected using lipofectamine with Silencer Select siRNA 
oligonucleotides at final concentration of 10 nM. The siR-
NAs used were silencer select negative control n.1 and Prkcβ 
mouse (catalogue numbers 4390843 and s71692, respec-
tively, Thermofisher, UK).
CD40L pull down
For the analysis of protein interactions of CD40L after 
activating reverse signaling, 8 day cultures of hippocampal 
neurons from Cd40−/− mice were treated for 30 min with 
either CD40-Fc or control Fc (1 μg/ml). The neuron cells 
were then washed with ice-cold PBS, harvested, and lysed 
in ice-cold triton lysis buffer (NaCl 150 mM, EDTA 10 mM, 
Tris–HCl 10 mM pH7.4, 1% Triton X-100 and protease and 
phosphatase inhibitor cocktail mix (Protease/Phosphatase 
inhibitor cocktail, 5872, Cell Signaling)). After lysate clear-
ance by centrifugation at 4 °C for 20 min at 18,000×g and 
quantify for equal concentration, Fc fragments were pulled 
down from the supernatant by incubation overnight on an 
orbital shaker at 4 °C with protein G-Sepharose beads (Pro-
tein G Sepharose Fast Flow, P3296, Sigma, UK) previously 
blocked with 5% BSA. The beads were then washed 5×with 
ice-cold triton lysis buffer. Complexes were collected with 
0.1 M pH 2.5 elution citrate buffer. The pH was adjusted by 
adding 1/6 neutralizing Tris HCl 1 M pH 8.5 buffer and after 
adding Laemmli buffer samples were boiled for analysis by 
immunoblotting.
Immunoblotting
Dissected hippocampi from mice at 18 days embryonic 
(E18), postnatal at day 0 (P0), day 3 (P3), day 6 (P6), day 
9 (P9) and adult (> 3 months) were placed in triton lysis 
buffer supplemented with protease and phosphatase inhibi-
tor cocktail mix (protease/phosphatase inhibitor cocktail, 
5872, Cell Signaling). The tissue was disaggregated using 
a pellet pestle until complete homogenized. For the cul-
tured neurons from Cd40−/− mice, after the indicated treat-
ments neurons were scraped out of the plates in ice-cold 
PBS, collected by centrifugation at 4 °C for 5 min at 200×g
and resuspended in ice-cold triton lysis buffer. Before pro-
tein separation by immunoblotting, samples in triton lysis 
buffer were cleared of debris by centrifugation at 4  °C 
for 20 min at 18,000× g. For the preparation of cytosolic 
and nuclear extracts, neurons were resuspended in buffer 
A (10 mM Hepes pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 
0.5 mM dithiothreitol (DTT) plus protease and phosphatase 
inhibitor cocktail mix). Nonidet P40 was added to a final 
concentration of 0.6% and vortexed for 10 s. Nuclei were 
separated from the cytosolic extracts by centrifugation at 
4 °C for 1 min at 1000×g. The nucleus fractions were then 
washed once with buffer A and then incubated with buffer 
B (20 mM Hepes pH 7.9, 25% glycerol, 400 nM NaCl, 
1 mM ethylenediamine tetraacetic acid (EDTA), 0.5 mM 
dithiothreitol (DTT) plus protease and phosphatase inhibi-
tor cocktail mix) for 30 min with gentle rocking at 4 °C. The 
suspensions were centrifugated at 15,000×g for 15 min at 
4 °C. Equal quantities of protein were separated on 10% 
SDS-PAGE gels and were transferred to PVDF membranes 
(Immobilon-P, Millipore, UK). The blots were probed with 
anti-phospho-PKCThr514 (1:1000 (0.101 μg/ml); rabbit 9379, 
Cell Signaling), anti-PKC (1:1000; mouse clone M110 
05–983, MERCK), anti-phospho-p44/p42Thr202/Tyr204 MAPK 
(ERK1/2) (1:1000 (0.191 μg/ml); rabbit 9101, Cell Sign-
aling), anti-p44/p42 (ERK1/2) (1:1000 (75 ng/ml); mouse 
9107, Cell Signaling), anti-phospho-SAPK/JNKThr183/Tyr185
(1:1000 (0.27 μg/ml); rabbit 4671, Cell Signaling), anti-
CD40L (1:700 (0,71 μg/ml); rabbit ab2391, AbCam, Cam-
bridge, UK), anti-Syk (1:1000 (73 ng/ml); rabbit 2712, Cell 
Signaling) which detects the 72 kDa and the 40 kDa because 
it is generated using an epitope at the carboxyl terminal, 
anti-PKCβI/II (1:1000 (1  μg/ml); rabbit SAB4502358, 
Sigma), anti-PKCγ (1:1000 (0.196 μg/ml); rabbit 43806, 
Cell Signaling) and anti-βIII tubulin (1:90,000 (5.55 ng/ml); 
mouse MAB1195, R&D). Binding of the primary antibodies 
was visualized with HRP-conjugated donkey anti-rabbit or 
anti-mouse secondary antibodies (1:5000 (0.2 μg/ml); rab-
bit W4011, mouse W4021, Promega, Southampton, UK) 
P. Carriba, A. M. Davies 
1 3
How CD40L reverse signaling regulates axon and dendrite growth
1 3
and EZ-ECL kit Enhanced Chemiluminescence Detection 
Kit (Biological Industries, Geneflow Limited, Staffordshire, 
UK). Densitometry was carried out using ImageJ software 
(NIH) of the bands that correspond to the 80 and 82 kDa 
isoforms detected with anti-phosphoPKC, PKC and PKCβ 
(I/II), the 44 kDa and 42 kDa isoforms of ERK1 and ERK2, 
respectively, and the 46 kDa and 54 kDa isoforms of JNK.
Results
Phosphorylation of PKC, ERK, and JNK 
following activation of CD40L reverse signaling
CD40-activated CD40L-mediated reverse signaling is the 
mechanism involved in the regulation of the growth and 
elaboration of axons and dendrites in the hippocampus, 
without the involvement of forward signaling [18]. We 
used western blotting to assess the degree of phosphoryla-
tion and hence activation of PKC, ERK1/ERK2, and JNK 
in hippocampal pyramidal neuron cultures after CD40L 
reverse signaling was experimentally activated. To elimi-
nate the complication of endogenous CD40/CD40L sign-
aling confounding the analysis, experiments were carried 
out on pyramidal neurons cultured from Cd40−/− mice 
because CD40/CD40L signaling is eliminated in these neu-
rons. CD40L reverse signaling was specifically activated by 
treating these neurons with a chimeric CD40-Fc protein. Fc 
protein, which does not activate signaling, was used in place 
of CD40-Fc in control experiments. The chimeric CD40-Fc 
protein consists of the extracellular domain of CD40 linked 
to the Fc part of human IgG1 [15, 18]. The role CD40L 
reverse signaling in promoting dendrite and axon growth 
from hippocampal pyramidal neurons is based on the previ-
ously reported complete rescue of the reduced growth phe-
notype of cultured Cd40−/− neurons with CD40-Fc and the 
replication of the phenotype of Cd40−/− neurons in Cd40+/+
neurons by treating them with soluble CD40L, which com-
petes with endogenous membrane-integrated CD40L for 
binding to endogenous CD40 [18]. These latter analyses 
and experiments on neurons cultured from Cd40+/+ mice, 
which would be difficult to interpret, were not repeated here.
Cd40−/− neurons were initially grown without CD40-
Fc and Fc and were treated for different times with these 
reagents before lysates were analyzed by western blotting 
for the levels of particular phospho-proteins after a total of 
8 days in vitro. As noted previously [18] and verified here, 
we did not observe any difference in viability or cell density 
between neurons cultured from Cd40+/+ and Cd40−/− mice 
and between neurons cultured from Cd40−/− mice treated 
with either Fc or CD40-Fc. The neurons showed healthy 
morphologies without any sign of cell death (dead floating 
detached neurons, dying vacuolated neurons with shrunk 
soma) in all cultures. Antibodies that recognize phospho-
PKCThr514, phospho-ERK1/ERK2Thr202/Tyr204, and phospho-
JNKThr183/Tyr185 were used. To ensure similar gel loading, 
anti-βIII tubulin was used as the loading control for the 
cytosolic fraction (pPKC and pERK1/pERK2) and naph-
thol blue was used as the loading control for the nuclear 
fraction (pJNK).
All three phospho-proteins were detectable in unstimu-
lated cultures (0 h) and the levels were unchanged through-
out the observation period (30 h) by treatment with Fc con-
trol protein (Fig. 1). This suggests a degree of constituent 
activity in PKC, ERK1/ERK2, and JNK signaling pathways. 
There were significant increases in the levels of all three 
phospho-proteins in CD40-Fc-treated cultures compared 
with Fc-treated cultures, although there were differences in 
the time course of the increases (Fig. 1c). Whereas there 
were clear increases in pPKC and pJNK within 20 min, the 
increase in pERK1/pERK2 started to become evident after 
2 h of stimulation. Apart from a consistent and transient 
return of pJNK levels to baseline at 16 h and a return of 
pERK1/pERK2 to the baseline after 24 h, the levels of all 
phospho-proteins remained elevated during the first day. 
These results suggested that CD40L-mediated reverse sign-
aling increases the phosphorylation and activation in all 
three signaling pathways.
Pharmacological manipulation of dendrite and axon 
growth from cultured hippocampal pyramidal 
neurons
To begin to investigate the significance of PKC, ERK1/
ERK2, and JNK in the enhanced dendrite and axon growth 
response to CD40L reverse signaling, we used specific 
inhibitors and activators of the PKC, ERK1/ERK2, and JNK 
signaling pathways. In these experiments, pharmacological 
reagents plus either CD40-Fc or Fc were added 24 h after 
plating the neurons which were imaged and analyzed 8 days 
later (Fig. 2a). While activation of signaling pathways was 
evident on western blots shortly after stimulation, it takes 
much longer to observe and quantify the changes produced 
Fig. 1 Phosphorylation of PKC, ERK1/ERK2, and JNK after stimu-
lating CD40L reverse signaling. a, b Schematic illustrations of the 
experimental protocols and representative Western blots of lysates of 
Cd40−/− E18 hippocampal neuron cultures treated for the indicated 
times with 1 μg/ml CD40-Fc (a) or 1 μg/ml Fc protein as a control 
(b). Lysates were prepared from all cultures after a total of 8  days 
in vitro. The blots were labeled with anti-phopho-PKCThr514 (pPKC), 
anti-phospho-p44/p42Thr202/Tyr204 MAPK (ERK1/2) (pERK 1/2), anti-
phospho-SAPK/JNKThr183/Tyr185 (pJNK). Anti-PKC (PKC), anti-p44/
p42 (ERK1/2), and anti-βIII tubulin (βIII tub) were used as loading 
control for the cytosolic fractions and naphthol blue was used as load-
ing control in the nuclear fraction. c Densitometry of at least three 




Fig. 2 Photomicrographs of Fc-treated and CD40-Fc-treated hip-
pocampal pyramidal neurons exposed to pharmacological reagents. 
a Schematic illustration of the experimental protocol. Treatment rea-
gents were added 24 h after plating. At 7 days in vitro, cultures were 
transfected with GFP expression vector and were fixed 2 days later. 
b–e Cultures of hippocampal neurons were established from E18 
Cd40+/+ (b) and Cd40−/− (c–e) embryos. The cultures were treated 
with either 1 μg/ml of CD40-Fc or 1 μg/ml of control Fc (b) together 
with pharmacological manipulators of PKC (either 500 nM PMA or 
500 nM Go6983) (c), ERK1/ERK2 (either 1 μM Fis or 1 μM U0126) 
(d), and JNK (either 50 nM Ani or 1 μM SP600125) (e). Representa-
tive images are shown with scaled sketches of the neuron with the 
axon in white and dendrites in red. Scale bar, 100 μm
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by these reagents on axon and dendrite growth. Dendrites 
and axons were clearly distinguishable by their morphology, 
which permitted their lengths to be separately quantified [13, 
25, 26].
We have previously shown that hippocampal pyrami-
dal neurons cultured from Cd40−/− embryos replicate the 
in vivo phenotype of these neurons and that activation 
of CD40L reverse signaling by treatment with a CD40-
Fc chimera recovers the wild-type phenotype [18]. As a 
starting point, this important observation was replicated 
and is illustrated in Fig. 2b. Fc-treated hippocampal neu-
rons cultured from Cd40+/+ embryos exhibited exuberant 
neurite outgrowth compared with Fc-treated neurons cul-
tured from Cd40−/− embryos. Treatment of neurons from 
Cd40−/− embryos with CD40-Fc promoted exuberant neurite 
similar to that observed in wild-type neurons.
Representative images of Fc-treated and CD40-Fc-treated 
Cd40−/− hippocampal pyramidal neurons exposed to differ-
ent pharmacological reagents are shown in Fig. 2c–e and 
quantification of dendrite and axon lengths of multiple neu-
rons are shown in Fig. 3. We first confirmed our published 
findings that the pan-PKC inhibitor Go6983 prevented the 
in vitro rescue of the phenotype of CD40-deficient neurons 
with CD40-Fc (Fig. 2c). There were no significant differ-
ences in dendrite length (Fig. 3a) and axon length (Fig. 3d) 
between neurons treated with CD40-Fc plus Go6983 and 
neurons treated with either Fc protein or Go6983 alone. 
Mimicking PKC activation with phorbol-12-myristate 
13-acetate (PMA), an analogue of diacylglycerol that acti-
vates conventional PKCs (PKCα, PKCβ, and PKCγ) and 
novel PKCs (PKCδ, PKCε, PKCθ, and PKCη) [28], had very 
similar effects on dendrite and axon growth from CD40-defi-
cient pyramidal neurons as CD40-Fc treatment (Figs. 2c, 3a, 
d). These observations confirm the importance of PKC acti-
vation in mediating the dendrite and axon growth responses 
of pyramidal neurons to CD40L reverse signaling.
Activation of ERK1/ERK2 was prevented by treating the 
neurons with U0126, a selective MEK1/MEK2 inhibitor 
that interferes with MEK1/MEK2-dependent activation of 
ERK1/ERK2. U0126 prevented rescue of the reduced den-
drite growth phenotype of Cd40−/− pyramidal neurons by 
CD40-Fc (Fig. 2d). There were no significant differences 
in dendrite length (Fig. 3b) and axon length (Fig. 3e) of 
Cd40−/− pyramidal neurons treated with CD40-Fc plus 
U0126 and neurons treated with Fc protein. There were 
also no significant changes in dendrite and axon lengths 
between Cd40−/− pyramidal neurons treated with Fc and 
U0126, showing that U0126 has no effect on dendrite and 
axon growth alone. U0124, the control inactive U0126 ana-
logue, did not prevent the rescue of the reduced dendrite 
and axon growth phenotype from Cd40−/− pyramidal neu-
rons by CD40-Fc and had no effect on dendrite and axon 
growth alone (not shown). ERK1/ERK2 was activated by 
the flavonoid fisetin (Fis) [29, 30]. Fis treatment restored 
the reduced dendrite and axon growth phenotype of 
Cd40−/− pyramidal neurons as effectively as CD40-Fc and 
did not significantly affect the extent of dendrite and axon 
growth from Cd40−/− pyramidal neurons treated with CD40-
Fc (Figs. 2d, 3b, e). Taken together, these results suggest 
that ERK1/ERK2 activation contributes to the dendrite and 
axon growth responses of hippocampal pyramidal neurons 
to CD40L reverse signaling.
In contrast to the importance of PKC and ERK1/ERK2 
activation in enhancing dendrite and axon growth in 
response of hippocampal neurons to CD40L reverse sign-
aling, pharmacological manipulation of JNK activity sug-
gested that it has the opposite effect on dendrite and axon 
growth. SP600125, which prevents JNK activation [31], did 
not prevent CD40-Fc from rescuing the short neurite pheno-
type of Cd40−/− pyramidal neurons (Fig. 2e). There was no 
significant difference in dendrite length of Cd40−/− pyrami-
dal neurons treated CD40-Fc plus SP600125 compared with 
neurons treated with CD40-Fc alone (Fig. 3c). There was 
only a small statistically significant reduction in axon length 
in neurons treated with CD40-Fc plus SP600125 compared 
with those treated with CD40-Fc alone (Fig. 3f). Moreover, 
SP600125 promoted dendrite and axon growth as effectively 
as CD40-Fc (Fig. 3c, f). This suggests the JNK activation 
is not required for the growth response of pyramidal neu-
rons to CD40L reverse signaling. Accordingly, anisomycin 
(Ani), a translational inhibitor secreted by Streptomyces 
which activates JNK [32], did not enhance dendrite and 
axon growth from pyramidal neurons but prevented CD40-
Fc from enhancing dendrite and axon growth (Fig. 3c, f). 
This suggests that JNK activity is inversely related to the 
extent of dendrite and axon growth and that it can override 
the growth-promoting action of CD40L reverse signaling. 
Taken together, the above findings suggest that PKC and 
ERK1/ERK2 activity and JNK activity have opposing influ-
ences on dendrite and axon growth from pyramidal neurons 
in response to CD40L reverse signaling.
The eects of manipulating signaling pathways 
in combination
In the experiments of the last section, we studied the influ-
ence of PKC, ERK, and JNK in regulating the growth 
response of pyramidal neurons to CD40-activated CD40L 
reverse signaling. To gain an understanding of the rela-
tive importance of PKC, ERK and JNK, and their potential 
functional interactions in regulating the growth response of 
pyramidal neurons to CD40-activated CD40L reverse sign-
aling, we studied the effects of pharmacological reagents 
in combination. To simplify these experiments, we treated 
Cd40−/− pyramidal neurons with CD40-Fc and either acti-
vated or inhibited JNK, PKC, and ERK1/ERK2 either alone 
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or together with a pharmacological reagent that manipulates 
each of the other pathways in a way that has the opposite 
effect on growth. For example, CD40-Fc-stimulated neurons 
were treated with Ani (which activates JNK and inhibits the 
CD40-Fc growth response) either alone or in combination 
with either PMA or Fis (which promote growth by activating 
PKC and ERK1/ERK2, respectively). The protocol for this 
experiment was the same as for the individual treatments, 
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i.e., neuronal cultures were treated 24 h after plating with 
the combined reagents and analyzed after a total of 9 days 
in vitro. For comparison, we measured dendrite and axon 
growth from neurons treated with either CD40-Fc or Fc 
alone. Quantification of dendrite length and axon length in 
these experiments is shown in Figs. 4 and 5, respectively.
The extent of dendrite and axon growth from pyrami-
dal neurons treated with Ani, which eliminated CD40-Fc-
promoted dendrite and axon growth (Figs. 3, 4a and 5a), 
was unaffected by concomitant treatment of these neurons 
with either PMA or Fis, which otherwise promoted dendrite 
and axon growth as effectively as CD40-Fc alone (Fig. 3). 
Figures 4a and 5a show that there were no significant dif-
ferences in CD40-Fc-promoted dendrite and axon length in 
cultures treated with Ani and cultures treated with either 
Ani plus PMA or Ani plus Fis. This suggests that the growth 
inhibitory effect of JNK activation on CD40-Fc-promoted 
dendrite and axon growth is dominant to the growth-promot-
ing effect of PKC and ERK1/ERK2 activation.
The inactivation of JNK with SP600125, which pro-
moted dendrite and axon growth as effectively as CD40-
Fc and did not interfere with CD40-Fc-promoted growth 
(Figs. 3, 4a and 5a), was partially reduced by concomitant 
treatment with either Go6083 or U0126, that otherwise 
completely eliminated CD40-Fc-promoted dendrite and 
axon growth (Fig. 3). Interestingly, there were differences 
in the responses to dendrites and axons to combined rea-
gents. Whereas there were significant reductions in dendrite 
length in cultures treated with SP600125 plus Go6083 and 
SP600125 plus U0126 compared with cultures treated with 
SP600125 alone (Fig. 4a), a significant reduction in axon 
length was only observed in cultures treated with SP600125 
plus Go6083 compared with cultures treated with SP600125 
alone (Fig. 5a). This suggests that PKC activity and ERK1/
ERK2 activity are able to modulate dendrite growth when 
JNK activity is reduced and that only PKC activity is able to 
modulate axon growth when JNK activity is reduced.
The activation of PKC with PMA, which promoted den-
drite and axon growth as effectively as CD40-Fc (Figs. 3, 
4b and 5b), was unaffected by concomitant treatment with 
U0126 which otherwise eliminates CD40-Fc-promoted 
growth (Fig. 3). Figures 4b and 5b show that there were 
no significant differences in CD40-Fc-promoted dendrite 
and axon length in cultures treated with PMA and cultures 
treated with either PMA plus U0126. Accordingly, the inac-
tivation of PKC with Go6083, which completely eliminated 
CD40-Fc-promoted dendrite and axon growth (Figs. 3, 4b 
and 5b), was unaffected by the concomitant presence of Fis 
which otherwise promoted dendrite and axon growth as 
effectively as CD40-Fc (Fig. 3). Figures 4b and 5b show that 
there were no significant differences in dendrite and axon 
length in cultures treated with Fis plus Go6083 compared 
with cultures treated with Go6083 alone. Taken together, 
these observations suggest that the influence of PKC activity 
on dendrite and axon growth is dominant to ERK1/ERK2 
activation.
In agreement with the predominant role of JNK and PKC 
over ERK1/ERK2 in CD40-Fc promoted growth, the den-
drite and axon length observed when ERK1/ERK2 path-
way was manipulated was altered when we manipulated the 
other two pathways. Activation of ERK1/ERK2 with Fis, 
which promoted dendrite and axon growth as effectively as 
CD40-Fc (Figs. 3, 4c and 5c), was significantly reduced by 
concomitant treatment with Go6083 or Ani, that otherwise 
eliminate CD40-Fc-promoted growth (Fig. 3). Figures 4c 
and 5c show that there were significant differences in CD40-
Fc-promoted dendrite and axon length in cultures treated 
with Fis and cultures treated with either Fis plus Go6983 or 
Fis plus Ani. The complete elimination CD40-Fc-promoted 
dendrite and axon growth by inactivation of ERK1/ERK2 
with U0126 (Figs. 3, 4c and 5c) was partially prevented by 
concomitant treatment with PMA and SP600125. As shown 
above, there was a difference between the responses of den-
drites and axons to combinations of pharmacological rea-
gents SP600125 and U0126. Whereas PMA caused a signifi-
cant reversal of the inhibition of CD40-Fc-induced dendrite 
growth by U0126 (Fig. 4c), both PMA and SP600125 each 
Fig. 3 Quantification of the influence of pharmacological reagents on 
dendrite and axon growth from hippocampal pyramidal neurons. a–f
Scatter charts of total dendrite lengths (a–c) and axon lengths (d–f) 
of hippocampal pyramidal neurons of E18 Cd40−/− embryos cultured 
for 9  days. The neurons were treated 24  h after plating with either 
1 μg/ml CD40-Fc (grey bars) or 1 μg/ml control Fc (clear bars) and 
either received no further treatment or were also treated at this time 
with the pharmacological reagents indicated: 500 nM PMA, 500 nM 
Go6983 (a and d), 1 μM Fis, 1 μM U0126 (b and e), 50 nM Ani and 
1  μM SP600125 (c and f). The mean±s.e.m of at least three inde-
pendent experiments is shown. The dots represent the data obtained 
from individual neurons (mean of>60 neurons per condition). One-
way ANOVA with multiple Newman–Keuls statistical comparison. 
Graphs show the statistical significance of the drugs in the presence 
of Fc (control) or CD40-Fc (when CD40L reverse signaling is acti-
vated), and as a reference between Fc and CD40-Fc, ***p<0.001 
and *p<0.05. The rest of statistical comparisons was as follows: 
Dendrites: PKC: ***p<0.001 (PMA vs Go6983) (PMA vs CD40-
Fc+Go6983) (Go6983 vs CD40-Fc); *p<0.05 (PMA vs CD40-
Fc+PMA). ERK1/2: **p<0.01 (Fc vs CD40-Fc+Fis) (Fis vs
CD40-Fc+U0126) (U0126 vs CD40-Fc); *p<0.05 (Fis vs U0126) 
(CD40-Fc+Fis vs CD40-Fc+U0126). JNK: ***p<0.001 (Fc vs 
CD40-Fc+SP600125) (Ani vs SP600125) (Ani vs CD40-Fc) (Ani 
vs CD40-Fc+SP600125) (SP600125 vs CD40-Fc+Ani) (CD40-
Fc+Ani vs CD40-Fc+SP600125). Axons: PKC: ***p<0.001 (Fc vs
CD40-Fc+PMA) (PMA vs Go6983) (PMA vs CD40-Fc+Go6983) 
(Go6983 vs CD40-Fc) (Go6983 vs CD40-Fc+PMA) (CD40-
Fc+PMA vs CD40-Fc+Go6983); *p<0.05 (PMA vs CD40-Fc). 
ERK1/2: ***p<0.001 (Fc vs CD40-Fc+Fis) (Fis vs U0126) (Fis 
vs CD40-Fc+U0126) (U0126 vs CD40-Fc) (U0126 vs CD40-
Fc+Fis) (CD40-Fc+Fis vs CD40-Fc+U0126). JNK: ***p<0.001 
(Fc vs CD40-Fc+SP600125) (Ani vs SP600125) (Ani vs CD40-
Fc) (SP600125 vs CD40-Fc+Ani); **p<0.01 (Ani vs CD40-




Fig. 4 The influence of 
pharmacological reagents in 
combination on dendrite growth 
from hippocampal pyramidal 
neurons. a–c Scatter charts of 
total dendrite lengths of hip-
pocampal pyramidal neurons of 
E18 Cd40−/− embryos cultured 
for 9 days in vitro and treated 
24 h after plating with 1 μg/
ml CD40-Fc (grey bars) plus 
either activators or inhibitors 
of JNK (a), PKC (b) or ERK1/
ERK2 (c) in combination with 
the activators or/and inhibitors 
of the other two pathways (the 
same concentrations were used 
as in Fig. 3). For comparison, 
dendrite lengths of neurons in 
cultures treated with 1 μg/ml 
control Fc alone (clear bars) 
are shown. The mean±s.e.m 
of at least three independent 
experiments is shown. The dots 
represent the data obtained 
from individual neurons (mean 
of>50 neurons per condition). 
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Fig. 5 The influence of 
pharmacological reagents in 
combination on axon growth 
from hippocampal pyramidal 
neurons. a–c Scatter charts of 
total axons lengths of hip-
pocampal pyramidal neurons of 
E18 Cd40−/− embryos cultured 
for 9 days in vitro and treated 
24 h after plating with 1 μg/
ml CD40-Fc (grey bars) plus 
either activators or inhibitors 
of JNK (a), PKC (b) or ERK1/
ERK2 (c) in combination with 
the activators or/and inhibitors 
of the other two pathways (the 
same concentrations were used 
as in Fig. 3). For comparison, 
axon lengths of neurons in 
cultures treated with 1 μg/ml 
control Fc alone (clear bars) 
are shown. The mean±s.e.m 
of at least three independent 
experiments is shown. The dots 
represent the data obtained 
from individual neurons (mean 
of>50 neurons per condition). 






caused significant reversals of the inhibition of CD40-Fc-
induced axon growth by U0126 (Fig. 5c).
In summary, these results indicate that inactivation of 
JNK is required for the dendrite and axon growth responses 
of pyramidal neurons to CD40-Fc and that activation of JNK 
is able to abolish the CD40-Fc growth responses. Moreo-
ver, the effect of JNK activity on dendrite and axon growth 
overrides that of PKC and ERK activity. Whereas, enhanced 
PKC activity and enhanced ERK activity increase growth, 
the influence of ERK activity on growth is modulated by 
PKC activity. These results imply that JNK, PKC, and ERK 
participate in an interacting network that regulates growth.
Activity of signaling pathways 
following pharmacological manipulation
We used western blotting to access the degree of phos-
phorylation and hence activity of JNK, PKC, and ERK1/
ERK2 following pharmacological manipulation of these 
signaling pathways. Neurons were plated with complete 
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medium and 8 days later, neurons were treated for 6 h with 
either Fc or CD40-Fc with and without pharmacological 
reagents that either inhibit or activate different pathways 
singularly and in combination (Fig. 6a). After 6 h, when all 
three phospho-proteins were clearly increased by CD40-Fc 
treatment (Fig. 1), lysates were probed for either phospho-
JNK, phospho-PKC or phospho-ERK1/phospho-ERK2. The 
aim of these studies was to determine the extent to which 
pharmacological manipulation of either one signaling path-
way or two pathways in combination affected activity of the 
other pathway in the presence and absence of CD40-Fc. Fig-
ure 6b–d show representative western blots for pJNK, pPKC, 
and pERK1/pERK2, respectively, and Fig. 6e–g summary 
the densitometry from multiple blots.
There were highly significant increases in pJNK, pPKC, 
and pERK1/pERK2 in CD40-Fc-treated cultures compared 
with Fc-treated cultures, confirming that CD40L reverse 
signaling enhanced phosphorylation of each signaling pro-
tein by 6 h (Fig. 6e–g). In the absence of CD40L reverse 
signaling, the level of pJNK was significantly increased by 
either activation or inactivation of PKC (Fig. 6e). In the 
presence of CD40L reverse signaling, activation of PKC 
also significantly increased the level of pJNK relative to its 
level in cells treated with CD40-Fc alone, but inactivation of 
PKC significantly decreased the level of pJNK (Fig. 6e). In 
the absence of CD40L reverse signaling, the level of pJNK 
was not significantly affected by either activation or inacti-
vation of ERK1/ERK2 (Fig. 6e). In the presence of CD40L 
reverse signaling, activation of ERK1/ERK2 significantly 
decreased the level of pJNK. While activation of PKC alone 
significantly increased the level of pJNK, PMA in combi-
nation with either Fis or U0126, that alone produce low 
levels of pJNK, caused further significant increases in the 
level of pJNK. Interestingly, although activation of ERK1/
ERK2 and inactivation of PKC each caused small, signifi-
cant decreases in the level of pJNK, when Fis and Go6983 
were used in combination, there was a significant increase 
in the level of pJNK in CD40-Fc-treated neurons (Fig. 6e). 
These findings show that when CD40L reverse signaling is 
activated, the level of pJNK is regulated by both PKC and 
ERK. Furthermore, manipulation of PKC and ERK activity 
simultaneously (see CD40-Fc+Go6983+Fis) had distinc-
tive effects on pJNK levels in the presence of CD40L com-
pared with the individual treatments (CD40-Fc+Go6983 
and CD40-Fc+Fis). Remarkably, in all combinations in 
which PKC was activated, independently of the activation 
state of ERK1/ERK2, the levels of pJNK were elevated.
In the absence of CD40L reverse signaling, the level of 
pPKC was significantly increased by either activation or 
inactivation of JNK (Fig. 6f). However, in the presence of 
CD40L reverse signaling, neither activation nor inactivation 
of JNK activation significantly affected the level of pPKC 
(Fig. 6f). In the absence of CD40L reverse signaling, the 
level of pPKC was significantly increased by ERK1/ERK2 
activation, but not significantly affected by ERK1/ERK2 
inactivation. However, in the presence of CD40L reverse 
signaling, ERK1/ERK2 activation had no significant effect 
on the level of pPKC and ERK1/ERK2 inactivation signifi-
cantly decreased the level of pPKC. When the activity of 
ERK1/ERK2 and JNK was manipulated simultaneously in 
the presence of CD40L reverse signaling, somewhat greater 
and distinctive effects on the level of pPKC were observed 
compared with the individual treatments. For example, JNK 
inactivation together with either ERK1/ERK2 inactivation or 
ERK1/ERK2 activation caused highly significant increases 
the level of pPKC (Fig. 6f). The above results show that 
when CD40L reverse signaling is activated, the level of 
pPKC is regulated by both JNK and ERK in distinctive ways.
In the absence of CD40L reverse signaling, the level of 
pERK1/pERK2 was significantly increased by all pharma-
cological manipulations of JNK and PKC: activation and 
inactivation of JNK and activation and inactivation of PKC 
(Fig. 6g). A significant effect on the levels of pERK was 
observed when CD40L reverse signaling was activated com-
pared with the absence of this activation. However, in the 
presence of CD40L reverse signaling, significant changes 
in the levels of pERK were observed with only two phar-
macological manipulations of JNK and PKC: both PKC 
Fig. 6 Regulation of JNK, PKC, and ERK1/ERK2 phosphorylation 
by pharmacological reagents in hippocampal neurons in the presence 
and absence of CD40L reverse signaling. a Schematic illustration of 
the experimental protocol. The neurons were treated 8 days after plat-
ing with either 1 μg/ml CD40-Fc or 1 μg/ml control Fc in combina-
tion with the reagents indicated for 6 h. The concentrations were the 
same as those indicated in Fig. 3. b–d Representative western blots 
of lysates of hippocampal neuron of Cd40−/− E18 embryos. The 
western blots were probed with anti-pJNK after treatment with acti-
vators and inhibitors of PKC and ERK1/ERK2 (b), anti-pPKC after 
treatment with activators and inhibitors of ERK1/ERK2 and JNK (c) 
and pERK1/ERK2 after treatment with activators and inhibitors of 
PKC and JNK (d). Anti-βIII tubulin was used to normalize western 
blots of cytosolic fractions and Naphthol blue for the nuclear frac-
tions. e–g Quantification of at least three independent western blots. 
The grey bars show combined treatments in the presence of 1 μg/ml 
CD40-Fc and the clear bars show combined treatments in the pres-
ence of 1  μg/ml Fc. The mean±s.e.m is indicated (***p<0.001, 
**p<0.01 and *p<0.05, one-way ANOVA with multiple Newman-
Keuls statistical comparison). Statistical not presented in the graphs 
were as follows: e, pJNK ***p<0.001 (CD40-Fc+U0126 vs CD40-
Fc+PMA+U0126) (CD40-Fc+Fis vs CD40-Fc+PMA+Fis) 
(CD40-Fc+Fis vs CD40-Fc+Go6983+Fis) (CD40-Fc+Go6983 
vs CD40-Fc+Go6983+Fis); f, pPKC ***p<0.001 (CD40-Fc+Fis 
vs CD40-Fc+Fis+Ani) (CD40-Fc+Ani vs CD40-Fc+Fis+Ani) 
(CD40-Fc+U0126 vs CD40-Fc+U0126+SP600125) (CD40-
Fc+Fis vs CD40-Fc+Fis+SP600125) **p<0.01 (CD40-
Fc+SP600125 vs CD40-Fc+U0126+SP600125) *p<0.05 
(CD40-Fc+SP600125 vs CD40-Fc+Fis+SP600125); g, pERK1/2 
**p<0.01 (CD40-Fc+PMA vs CD40-Fc+PMA+Ani) (CD40-
Fc+Ani vs CD40-Fc+PMA+Ani) (CD40-Fc+Go6983 vs CD40-





inhibition and PKC activation together with JNK activation 
caused significant reductions in the level of pERK com-
pared with CD40-Fc treatment (Fig. 6g). The above results 
show that the level of pERK is regulated by both JNK and 
PKC, although not as extensively in the presence of CD40L 
reverse signaling. Overall, with the presence of CD40-Fc, 
the regulation of pERK levels by JNK and PKC was not as 
great as the regulation of pJNK by PKC and ERK and the 
regulation of pPKC by JNK and ERK.
Taken together, the above results suggest that when 
CD40L was activated, JNK, PKC, and ERK influence the 
activity of one another and function as regulatory network, 
with distinctive dynamics. These findings suggest that JNK, 
PKC, and ERK signaling pathways regulate neural process 
growth by acting as an interacting network rather than acting 
in simple linear sequence.
The Syk tyrosine kinase as a candidate to be a link 
between CD40L and PKC
To provide a more detailed understanding of how the CD40L 
reverse signaling receptor links to the intracellular signal-
ing network, we attempted to identify membrane-associated 
molecular components of the activated CD40L receptor 
complex. Previous work using specific siRNAs to different 
PKC isoforms has shown that PKCβ is the main isoform that 
mediates the neurite growth-promoting effects of CD40L 
reverse signaling in hippocampal pyramidal neurons [18]. 
Because PKC activation involves translocation of a latent 
form from the cytosol to the membrane [33], we initially 
used an in silico approach to determine possible protein–pro-
tein interactions (PPI) between CD40L and PKCβ using the 
STRING database (https://string-db.org/). Mouse CD40L 
and PKCβ were analyzed for all possible interactions (text-
mining, experiments, databases, co-expression, neighbor-
hood, gene fusion and co-occurrence) with reliability scores 
more than 0.4 (i.e., medium confidence and greater). Supple-
mentary Table 1 lists all annotated PPI with reliability scores 
of 0.4 and greater for CD40L and PKCβ separately and in 
common. Supplementary Table 2 shows the most relevant 
PPIs in common that might be involved in CD40L reverse 
signaling. These proteins not only include ERK1, ERK2, 
JNK1, JNK2, JNK3 and several ERK and JNK regulatory 
proteins, but also spleen tyrosine kinase (Syk). Syk is a non-
receptor tyrosine kinase that is most highly expressed in cells 
of the immune system. It is recruited to the cell membrane 
following activation of receptors of the adaptive immune 
response and plays a key role in signal transduction from 
the receptor complex [34]. In addition, recent work on Syk 
has been shown to mediate a variety of diverse biological 
functions in several different cell types [35]. Full-length Syk 
is a 72 kDa protein that is proteolytically cleaved to generate 
a 40 kDa fragment that contains the catalytic domain [36].
We used western blotting to analyze the expression of 
Syk in hippocampal lysates from Cd40+/+ and Cd40−/− mice 
over a range of ages. Both 40 kDa and 72 kDa components 
were detectable and displayed a similar pattern of expres-
sion in the hippocampi of Cd40+/+ and Cd40−/− mice (Fig. 
S1). The 40 kDa catalytic fragment was clearly expressed 
during the perinatal period up to P6, after which there was a 
clear decrease in expression with age (Fig. S1a). The expres-
sion of the 72 kDa full-length protein became evident at P3, 
and its level increased with age (Fig. S1a). Syk was also 
detectable in the lysates of hippocampal neuron cultures and 
the 40 kDa and 72 kDa also showed a reciprocal pattern of 
expression with time in culture. Whereas the 40 kDa frag-
ment was predominant up to 5 days in vitro, the full-length 
protein was predominant since 5–7 days in vitro (Fig. S1c).
We also analyzed the expression of PKCβ, PKCγ, and 
CD40L in hippocampal culture lysates. No remarkable dif-
ferences were observed in hippocampal lysates between 
Cd40+/+ and Cd40−/− in the expression of PKCβ (βI/II) 
and PKCγ (Fig. S1a). However, the expression of CD40L 
showed some differences between Cd40+/+ and Cd40−/−. 
In CD40-null animals, the expression of CD40L started at 
postnatal stages and displayed a peak between P3 and P6, 
while in wild-type mice, the expression began earlier and 
seemed more sustained within time with a peak in perinatal 
neurons (Fig. S1a). This pattern of CD40L expression was 
also observed in neurons cultured from Cd40−/− compared 
with neurons from Cd40+/+ (Fig. S1b). Comparable levels of 
expression of PKCβ and PKCγ were observed in hippocam-
pal neurons (Fig. S1c).
CD40-activated CD40L reverse signaling recruits Syk 
and PKCβ
While STRING predicted interaction between CD40L, Syk 
and PKCβ, we conducted immunoprecipitation experiments 
to determine if these proteins physically interact in culture 
following activation of CD40L reverse signaling by CD40-
Fc. In these experiments, we cultured E18 hippocampal 
pyramidal neurons from Cd40−/− mice for 8 days. These cul-
tures were treated with either CD40-Fc or Fc 30 min before 
extraction of lysates. After Fc fragments were pulled down 
in the lysates with protein G-Sepharose, we used western 
blotting to detect the presence of CD40L, Syk, PKCβ, and 
PKCγ (Fig. 7a). Quantification of associated proteins after 
IP is shown in Fig. 7b. As expected, we only detected the 
association of CD40L in samples treated with CD40-Fc but 
not in samples treated with Fc (Fig. 7a, b). We detected some 
unspecific interaction of full-length Syk in samples treated 
with Fc, but treatment with CD40-Fc increased its presence 
compared with Fc (Fig. 7a); however, this increase was not 
statistical significant (Fig. 7b). There was clear detection of 
the 40 kDa Syk catalytic fragment (Fig. 7a) with statistical 
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significance between neurons treated with CD40-Fc com-
pared with neurons treated with Fc (Fig. 7b). When we 
analyzed the G-Sepharose fraction for the two main PKCs 
involved in mediating the grow of processes in pyramidal 
neurons (PKCβ) and medium spiny neurons (PKCγ) [18], 
we only detected PKCβ, but not PKCγ, when CD40 reverse 
signaling was activated with CD40-Fc in Cd40−/− hip-
pocampal neurons (Fig. 7a, b). Both PKC isoforms were 
clear detectable in the lysates prior to G-Sepharose pull 
down (Fig. 7a).
Fig. 7 Pull down of Syk and PKCβ in Cd40−/− hippocampal neurons 
after CD40-activated CD40L reverse signaling. a Representative 
western blots of the expression of CD40L, Syk, PKCβ and PKCγ in 
Cd40−/− neurons from E18 embryos cultured for 8 days and treated 
for 30 min with either 1 μg/ml Fc or 1 μg/ml CD40-Fc, before pulled 
down Fc fragment (input) and after pulled down Fc fragment (IP). b
Quantification of three independent experiments of the quantity of 
CD40L, 40 kDa and 72 kDa Syk, PKCβ and PKCγ after IP normal-
izing with the total quantity of those proteins in the input. c Repre-
sentative western blots of the expression of CD40L, Syk, PKCβ, and 
PKCγ in Cd40−/− neurons transfected with control siRNA or PKCβ 
siRNA and treated for 30 min with 1 μg/ml CD40-Fc, before pulled 
down Fc fragment (input) and after pulled down Fc fragment (IP). d
Quantification of three independent experiments of the quantity of 
CD40L and 40 kDa Syk after IP normalizing with the total quantity 
of those proteins in the input. b and d ***p<0.001, **p<0.01 and 
*p<0.05 t test. *=non-specific band
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To analyze the involvement of PKCβ in these interac-
tions, we repeated the above experiments with prior PKCβ 
down-regulation. To down-regulate PKCβ, we used a 
specific siRNA and a scrambled siRNA control, as previ-
ously reported [18]. In these experiments, we observed 
clear reduction in the quantity of the 40 kDa Syk fragment 
(Fig. 7c, d) and did not detect any interaction with full-
length Syk (Fig. 7c). It is unclear why in this set of experi-
ments we did not detect the full-length protein. Because the 
antibody recognizes an epitope at the carboxyl terminal, the 
lack of detection of full-length protein raises the possibility 
that Syk may have undergone proteolytic degradation after 
stimulation with CD40-Fc generating the 40 kDa fragment. 
No differences were observed in the quantity of CD40L 
pulled down when PKCβ was down-regulated (Fig. 7c, d). 
Taken together, the above results suggest that activation of 
CD40L reverse signaling in hippocampal pyramidal neurons 
promotes the recruitment of Syk and PKCβ, but not PKCγ, 
to CD40L and that PKCβ is involved in the recruitment of 
Syk to this complex.
Discussion
Given the extensive physiological importance of CD40L 
reverse signaling in regulating the growth and elaboration 
of neural processes in the developing nervous system, the 
aim of the current study was to extend our understanding 
of the intracellular signaling events that mediate the effect 
of CD40L reverse signaling on axon and dendrite growth, 
focusing in on the well-characterized hippocampal pyrami-
dal neuron model. Moreover, by analyzing the participation 
of multiple signaling pathways in a given neuronal model 
that have been individually implicated in influencing axon 
and dendrite growth in a variety of neuronal models, we 
hoped to show how their function might be integrated in 
mediating growth responses to a particular physiologically 
important ligand.
Using a variety of specific pharmacological reagents, 
we demonstrated that proteins of three ubiquitous signaling 
pathways that have each been implicated in the regulation 
of axon and/or dendrite growth in several in vitro neuronal 
models all play a role in regulating the axon and dendrite 
growth responses of pyramidal neurons to CD40L reverse 
signaling. Either activators or inhibitors of JNK, PKC, and 
ERK1/ERK2 significantly affected in different ways the 
axon and dendrite growth responses of pyramidal neurons 
to CD40L reverse signaling. While western blotting showed 
that CD40L reverse signaling caused an increase in the 
phosphorylation (and hence the activity) of each of these 
proteins, experiments using pharmacological reagents sug-
gested that activity was not correlated with enhanced growth 
for each protein. Inhibitors of PKC and ERK1/ERK2 each 
eliminated CD40L-promoted dendrite and axon growth, 
and activators of these signaling proteins generally did not 
significantly affect CD40L-promoted growth (there was a 
small statistically reduction of CD40-Fc-promoted dendrite 
growth by PKC activation). Accordingly, activation of either 
PKC or ERK1/ERK2 in the absence CD40L reverse signal-
ing promoted the same degree of axon and dendrite growth 
as CD40L reverse signaling itself. However, JNK activa-
tion eliminated the dendrite and axon growth response to 
CD40L reverse signaling and JNK inactivation generally 
did not significantly affect the growth response to CD40L 
reverse signaling (there was a small statistically reduc-
tion of CD40-Fc-promoted axon growth by JNK inactiva-
tion). Accordingly, JNK inactivation in the absence CD40L 
reverse signaling promoted the same degree of axon and 
dendrite growth as CD40L reverse signaling itself. Taken 
together, these data suggest that, whereas PKC activation 
and ERK1/ERK2 activation play a role in CD40L-promoted 
growth, JNK inactivation is important for CD40L-promoted 
growth. Apart from the minor differences highlighted above, 
our findings suggest that these proteins play similar roles 
in axon growth and in dendrite growth from hippocampal 
pyramidal neurons.
Experiments using combinations of pharmacological 
reagents revealed the relative importance of PKC, ERK1/
ERK2, and JNK and their potential functional interactions 
in mediating the CD40L reverse signaling growth response. 
The demonstration that the elimination of the CD40-Fc-
promoted growth by JNK activation could not be prevented 
by concomitant activation of either PKC or ERK suggests 
that JNK inactivation is necessary for CD40-Fc-promoted 
growth and plays a more dominant role than PKC and 
ERK1/ERK2 activation. However, our finding that in the 
presence of JNK inactivation, inactivation of either PKC or 
ERK1/ERK2 significantly reduced, but did not eliminate, 
the CD40-Fc dendrite growth response suggests that PKC or 
ERK1/ERK2 is able to exert some influence on the CD40-
Fc growth response when JNK is reduced. Our demonstra-
tion that the elimination of the CD40-Fc growth response 
by PKC inactivation could not be prevented by ERK/ERK2 
activation and that ERK1/ERK2 inactivation did not elimi-
nate the CD40-Fc growth response in neurons in which PKC 
was activated suggests that PKC exerts a more dominant role 
than ERK1/ERK2 in the axon and dendrite growth responses 
of pyramidal neurons to CD40 reverse signaling. Putting all 
these observations together suggests that JNK, PKC, and 
ERK1/ERK2 do not mediate the growth response of pyrami-
dal neurons to CD40L reverse signaling by functioning in a 
simple linear sequence. Rather, they must functionally inter-
act to regulate the growth response.
Our study of the phosphorylation, and hence activation, 
of JNK, PKC, and ERK1/ERK2 in cultures treated with 
pharmacological reagents has given us further insight into 
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the regulation of intracellular signaling pathways down-
stream of CD40L reverse signaling. While the above func-
tional studies have demonstrated that JNK activity has a 
powerful, dominant inhibitory effect on the growth of neu-
ral processes, our phosphorylation studies clearly show 
that JNK activity is influenced by PKC and ERK1/ERK2 
activity, both alone and in combination. Interestingly, 
when the activity of PKC and ERK1/ERK2 was individu-
ally manipulated, only inhibition of ERK1/ERK2 reduced 
the phosphorylation of PKC and only inhibition of PKC 
reduced the phosphorylation of ERK1/ERK2. When we 
manipulated the two protein pathways, in a few instances, 
when the activity of one signaling pathway is activated or 
inactivated, positive or negative manipulation of a second 
pathway has the same effect on the phosphorylation level 
of the third. For example, when ERK1/ERK2 is activated, 
either activation or inactivation of PKC increases the level 
of pJNK, and when the activity of JNK is inactivated 
either activation or inactivation of ERK1/ERK2 increases 
the level of pPKC. These observations not only illustrate 
the interactions between two signaling pathways in influ-
encing the third but also suggest that a fine balance in level 
of activation of particular pathways influences the activity 
of the third. The potential interactions between JNK, PKC, 
and ERK1/ERK2 and their consequences on growing of 
the neuronal processes are summarized in Fig. 8. Supple-
mental Fig. 2 complements Fig. 8, showing the effect of 
all combinations of activators and inhibitors on dendrite 
and axon growth.
The control of neuronal process growth evolves over 
time, with several factors participating at different times. 
Temporal aspects of the interactions between JNK, PKC, 
and ERK1/ERK2 have not been addressed here, as the very 
extensive experimental work required to explore this defi-
nitely is beyond the scope of the current study. Nonetheless, 
we have shown that in the absence of pharmacological rea-
gents, the time course of enhanced JNK, PKC, and ERK1/
ERK2 phosphorylation following activation of CD40L 
reverse signaling differs for these three proteins. Perhaps 
activation of each protein contributes to different aspects of 
the growth response or even termination of this response. 
In this respect, it is curious that CD40L reverse signaling 
increases activity in all three pathways and yet increased 
JNK activity has a clear inhibitory effect on growth, whereas 
PKC and ERK1/ERK2 enhance growth. Perhaps the physi-
ological significance of enhanced JNK activation may 
be related to the control of the termination of the growth 
response.
Fig. 8 Schematic summary of the results. Graphic summary of the 
interactions between the PKC, ERK1/ERK2, and JNK downstream 
of the activation of CD40L reverse signaling. The direction of influ-
ence is indicated by the arrows (solid arrows indicate the influence of 
activation of these pathways and dashed arrows indicate the influence 
of inhibition of these pathways), change in the level of phosphoryla-
tion (+=increased phosphorylation and – =decreased phosphoryla-
tion) and the effect on neural process growth are documented. Acti-
vation of CD40L reverse signaling enhances the phosphorylation of 
JNK, PKC, and ERK1/ERK2. Phosphorylation of JNK is positively 
modulated by PKC and negatively modulated by ERK1/ERK2, while 
phosphorylation of PKC and ERK is reciprocally regulated (inhibi-
tion of ERK1/ERK2 reduces pPKC and inhibition of PKC reduces 
pERK1/pERK2). Activation of PKC and JNK reduce the phospho-
rylation of ERK1/ERK2, which enhances JNK phosphorylation 
with the concomitant restraint of growth. PKC activation promotes 
JNK phosphorylation independently of the ERK1/ERK2 status, with 
a positive net effect on growth compared to Fc, suggesting that the 
increase in the phosphorylation of JNK may lead to growth termina-
tion. However, the inhibition of PKC inhibits CD40L reverse signal-
ing-promoted growth, in both situations, when the inhibition of PKC 
is together with the activation of ERK1/ERK2 that increases the level 
of pJNK and when is together with the inhibition of ERK1/ERK2 that 
does not have any effect on the level of pJNK. The level of phospho-
PKC is modulated by activation or inactivation of JNK together with 
activation or inactivation ERK. However, increased growth was only 
observed when JNK was inactivated. This raises the possibility that 
the level of JNK activation may be a checkpoint loop that governs 




Another important aspect of our study was to address how 
intracellular signaling is initiated downstream of CD40L 
by determining and analyzing components of the potential 
CD40L receptor complex. In silico analysis initially sug-
gested that the Syk tyrosine kinase associates with CD40L 
and PKCβ, the PKC isoform that has shown to mediate the 
effects of CD40L reverse signaling on the growth of neu-
ral processes from hippocampal pyramidal neurons [18]. 
Immunoprecipitation studies subsequently suggested that 
Syk, CD40L, and PKCβ associate following activation of 
CD40L reverse signaling in hippocampal pyramidal neurons. 
PKCγ, the PKC isoform required for the effects of CD40L 
reverse signaling on dendrite growth from medial spiny neu-
rons [18], does not appear to be a component of the CD40L 
receptor complex in hippocampal pyramidal neurons. These 
data are consistent with extensive evidence that Syk and 
PKC are recruited to the membrane following activation of 
relevant receptors [33, 35]. Interestingly, T-lymphocyte acti-
vation via CD40L involves recruitment of p56lck and PKC 
to the membrane and is associated with strong activation of 
JNK [37, 38]. p56lck is a non-receptor tyrosine kinase that 
is structurally and functionally related to Syk [39].
In addition to Syk, in silico analysis suggests that com-
ponents of JNK, ERK, and ERK-activating enzymes associ-
ate with CD40L and PKCβ. Thus, it is possible that activa-
tion of CD40L reverse signaling initiates the formation of 
a receptor complex that includes all of intracellular signal-
ing elements we have studied. The physical interaction of 
these components may explain the functional interactions 
between PKC, ERK, and JNK that mediate and determine 
the consequences of activation of CD40L reverse signaling 
in hippocampal pyramidal neurons. Future work may reveal 
how such potential physical interactions might generate the 
complex interdependencies between PKC, ERK, and JNK 
that our work has revealed.
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